Why the study?
Does cardiomyocyte-specific NOS1 overexpression prevent heart failure progression in response to pressure overload in mice?
Does cardiomyocyte-specific NOS1 overexpression prevent heart failure progression in response to pressure overload in mice?
Cardiomyocyte NOS1 overexpression preserves calcium cycling and delays the transition to heart failure in a mouse model of chronic pressure overload.
Answers are grounded in this paper and cite their sources.
Cardiomyocyte NOS1 overexpression may preserve function in murine pressure overload; leaves open translation to human HF therapies.
BACKGROUND: Defects in cardiomyocyte Ca(2+) cycling are a signature feature of heart failure (HF) that occurs in response to sustained hemodynamic overload, and they largely account for contractile dysfunction. Neuronal nitric oxide synthase (NOS1) influences myocyte excitation-contraction coupling through modulation of Ca(2+) cycling, but the potential relevance of this in HF is unknown. METHODS AND RESULTS: We generated a transgenic mouse with conditional, cardiomyocyte-specific NOS1 overexpression (double-transgenic [DT]) and studied cardiac remodeling, myocardial Ca(2+) handling, and contractility in DT and control mice subjected to transverse aortic constriction (TAC). After TAC, control mice developed eccentric hypertrophy with evolution toward HF as revealed by a significantly reduced fractional shortening. In contrast, DT mice developed a greater increase in wall thickness (P<0.0001 versus control+TAC) and less left ventricular dilatation than control+TAC mice (P<0.0001 for both end-systolic and end-diastolic dimensions). Thus, DT mice displayed concentric hypertrophy with fully preserved fractional shortening (43.7+/-0.6% versus 30.3+/-2.6% in control+TAC mice, P<0.05). Isolated cardiomyocytes from DT+TAC mice had greater shortening, intracellular Ca(2+) transients, and sarcoplasmic reticulum Ca(2+) load (P<0.05 versus control+TAC for all parameters). These effects could be explained, at least in part, through modulation of phospholamban phosphorylation status. CONCLUSIONS: Cardiomyocyte NOS1 may be a useful target against cardiac deterioration during chronic pressure-overload-induced HF through modulation of calcium cycling.
No takes yet. Share an insight, caveat, or question.
Loyer et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: